Monotherapy of Nosocomial Pneumonia

H. Lode; M. Raffenberg; H. Geerdes-Fenge; H. Mauch

doi:10.1055/s-2000-9931

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2000; 21(1): 0009-0018
DOI: 10.1055/s-2000-9931

Monotherapy of Nosocomial Pneumonia

H. Lode¹ , M. Raffenberg¹ , H. Geerdes-Fenge¹ , H. Mauch²

¹Department of Chest and Infectious Diseases, Hospital Heckeshorn, affiliated Freie Universität Berlin, Berlin, Germany
²Institute for Medical Microbiology and Immunology, Hospital Heckeshorn, affiliated Freie Universität Berlin, Berlin, Germany

Abstract

ABSTRACT

Nosocomial pneumonia remains a common problem and is the leading cause of death among patients with nosocomial infection. However, the initial empiric therapy of nosocomial pneumonia is directed at the leading organisms common to all patients, and for many patients monotherapy is adequate for at least 48 hours, at which time the microbiological results of appropriate diagnostic procedures should be known and the treatment can be focused. The currently available antimicrobial agents such as third- and fourth-generation cephalosporins, piperacillin plus tazobactam, carbapenems, and some fluoroquinolones are highly active and bactericidal. They should be used in consideration of current pharmacodynamic knowledge, which will lead to convincing clinical results. Combination of antibiotics is necessary only in specific situations or for the amelioration of special pathogens, such as Pseudomonas aeruginosa, Acinetobacter spp., and against mixed aerobic and anaerobic infections.

KEYWORD

Nosocomial pneumonia - monotherapy - efficacy

Full Text

References

REFERENCES

1 Craven D E, Steger K A, Barat L M, Duncan R A. Nosocomial pneumonia: Epidemiology and infection control. Int Care Med . 1992; 18 53-59
2 Dal Nogare R A. Nosocomial pneumonia in the medical and surgical patients. Med Clin North Am . 1994; 78 1081-1090
3 Emori T G, Gaynes R P. An overview of nosocomial infections including the role of the microbiology laboratory. Clin Microbiol Rev . 1993; 8 428-442
4 Craven D E, Steger K A, Barat L M, Duncan R A. Nosocomial pneumonia: Epidemiology and infection control. Int Care Med . 1992; 18 53-59
5 American Thoracic Society. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Am J Respir Crit Care . 1996; 153 1711-1725
6 Vincent J I, Bihari D J, Surer P M, Bruining H A, White J, Nicolas-Chanoin M H. The prevalence of nosocomial infection in intensive care units in Europe. JAMA . 1995; 274 639-644
7 Francioli P, Chastre J, Langer M, Santos J I, Shah P M, Torres A. Ventilator-associated pneumonia. Understanding epidemiology and pathogenesis to guide prevention and empiric therapy. Clin Microbiol Infect . 1997; 3(suppl 1) 61-76
8 La Force M F. Systemic antimicrobial therapy of nosocomial pneumonia: Monotherapy versus combination therapy. Eur J Clin Microbiol Infect Dis . 1989; 8 61-68
9 Gribble M J, Chow A W, Naiman S C. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother . 1983; 24 388-393
10 Cometta A, Calandra T, Gaya H. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic cancer patients. Antimicrob Agents Chemother . 1996; 49 1108-1115
11 Fink M P, Snydman T R, Niederman M S. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother . 1994; 38 547-557
12 Jaccard C, Troillet N, Harbarth S. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother . 1998; 42 2966-2972
13 Taylor G D, Buchanan-Chell M, Kirkland T, McKenzie M, Wiens R. Bacteremic nosocomial pneumonia. A 7 year experience in one institution. Chest . 1995; 108 786-788
14 Brewer S C, Wunderick R G, Jones C B, Leeper K V. Ventilator-associated pneumonia due to Pseudomonas aeruginosa Chest . 1996; 109 1019-1029
15 Fagon J Y, Chastre J, Hance A J, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. Am J Med . 1993; 94 281-288
16 Hilf M, Yu V L, Sharp J, Zuravieff J J, Korvick J A, Muder R R. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med . 1989; 87 540-546
17 Rello J, Jubert P, Vallés J, Artigas A, Rué M, Niederman M S. Evaluation of outcome for patients with pneumonia due to Pseudomonas aeruginosa Clin Infect Dis . 1996; 23 973-978
18 Craig W A, Redington J, Ebert S C. Pharmacodynamics of amikacin in vitro and in mouse thigh infections. J Antibicrob Chemother . 1991; 27(suppl C) 29-40
19 Leggett J, Fantin B, Ebert S. Comparative antibiotic dose effect relations at several dosing intervals in murine pneumonitis and thigh infection models. J Infect Dis . 1988; 159 281-292
20 Schentag J J, Birminham M C, Paladino J A. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Semin Respir Infect . 1997; 4 278-293
21 Forrest A, Nix D E, Ballow C H. The parmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother . 1993; 37 1073-1081
22 Nix D E, Schentag J J. The role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12 hr cefotaxime alone and in combination with other antibiotics. Diag Microbiol Infect Dis . 1995; 22 71-76
23 Lode H, Schaberg T, Raffenberg M, Mauch H. Nosocomial pneumonia in the critical care unit. Crit Care Clin . 1998; 14 119-133
24 Chastre J, Fagon F, Trouillet J-L. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Clin Infect Dis . 1995; 21(suppl 3) 326-327
25 Mandell L A, Nicolle L E, Ronald A R. A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. J Antimicrob Ther . 1987; 20 95-107
26 Mangi R J, Greco T, Ryan J, Thornton G, Andriole V T. Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia. Am J Med . 1988; 84 68-74
27 Mouton Y, Deboscker Y, Bazin C. Etude prospective randomisée controlée imipénem-cilastatine versus céfotaxime-amikacine dans le traitement des infections respiratoires inférieures et des septicémies de réanimations. Presse Med . 1990; 19 607-612
28 Rubinstein E, Grassi C, Lode H. Ceftazidime monotherapy versus ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Clin Infect Dis . 1995; 20 1217-1228
29 Rello J, Ricart M, Ausina V, Net A, Prats G. Pneumonia due to Haemophilus influenzae among mechanically ventilated patients. Incidence, outcome, and risk factors. Chest . 1992; 102 1562-1565
30 Verbist L. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacteria isolates in Europe. The International Study Group. Scand J Infect Dis . 1991; 91 14-24
31 Wolff M, Carbon C, Fallissard B. Comparative study of cefpirome and ceftazidime in ICU patients with pneumonia. Presented at the 36th ICAAC, New Orleans, Louisiana, October 3-5, 1996
32 Arbo M DJ, Snydman D R. Monotherapy is appropriate for nosocomial pneumonia in the intensive care unit. Semin Resp Infect . 1993; 8 259-2671